SHS Capital buys majority stake in Basic Pharma, Brightlands Venture Partners exits

• SHS Capital acquired a majority stake in Basic Pharma, a Geleen-based pharmaceutical CDMO, in a transaction announced July 14, 2026.
• Brightlands Venture Partners exited its shareholding, ending its involvement alongside Particon and co-founder Jacques Havermans.
• Basic Pharma employs about 250 people, combining product development, regulatory services, and GMP manufacturing under one site in Geleen.
• CEO Bob Kool will remain in the role, reinvesting alongside SHS Capital; CFO Harry Relouw stays, while COO Cyrille De la Haye joins the board.
• SHS Capital backing will fund added production capacity, new product development, and international expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightlands Venture Partners BV published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.